Vanda Pharmaceuticals, Inc. (VNDA) Misses Q1 EPS by 49c
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Price: $5.04 -3.26%
Revenue Growth %: +24.1%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +24.1%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) reported Q1 EPS of ($0.79), $0.49 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $9.1 million versus the consensus estimate of $8.75 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals, Inc. (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oppenheimer Starts Vanda Pharmaceuticals (VNDA) at Outperform
- Scotiabank Reiterates Sector Outperform Rating on Ero Copper Corp. (ERO:CN) (ERO)
- Capitol Federal Financial names William Skrobacz Jr. as president
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
